Abbott CEO Robert Ford speaks on earnings call

Abbott CEO Robert Ford speaks on earnings call

Abbott Laboratories (NYSE: ABT) reported robust financial performance for the second quarter of 2025, with sales growth of 7.4 percent and organic sales growth of 6.9 percent, excluding COVID-19 testing-related sales [1]. The company's adjusted diluted EPS was $1.26, reflecting double-digit growth compared to the prior year. CEO Robert B. Ford expressed optimism about the company's momentum, projecting full-year 2025 organic sales growth of 7.5 percent to 8.0 percent, excluding COVID-19 testing-related sales, and adjusted diluted EPS of $5.10 to $5.20 [1].

The second quarter saw Abbott's sales increase 14.6 percent in the U.S. and 12.4 percent internationally, with organic growth rates of 14.6 percent and 12.2 percent, respectively [1]. The company's gross margin improved to 52.7 percent of sales, and the operating margin increased to 18.4 percent [1]. Abbott's medical devices segment experienced strong growth, with sales up 12.4 percent and organic sales growth of 12.2 percent [1].

In the second quarter, Abbott reported significant advancements in its product pipeline. The company completed enrollment ahead of schedule in its FlexPulse U.S. IDE trial, which aims to evaluate the TactiFlex™ Duo Pulsed Field Ablation (PFA) System for treating heart rhythm disorders such as atrial fibrillation (AFib) [1]. Abbott also announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) clinical feasibility study and received FDA approval for its Tendyne™ transcatheter mitral valve replacement (TMVR) system [1].

Looking ahead, Abbott has initiated plans to develop a new cardiovascular device manufacturing facility in Georgia, set to be completed by 2028 [1]. The company's CEO expressed confidence in the company's ability to sustain growth and momentum, stating, "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline. We see this momentum carrying into 2026" [1].

References:
[1] https://abbott.mediaroom.com/2025-07-17-Abbott-Reports-Second-Quarter-2025-Results